Dna X (SONM) EBITDA (2018 - 2026)

Dna X has reported EBITDA for 9 years, with the latest figure at -$3.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 315.86% year-over-year to -$3.6 million; the trailing twelve-month figure through Mar 2026 stood at -$9.7 million (down 654.8% YoY), and the FY2025 full-year result was -$5.4 million, down 74.39% from the prior year.
• EBITDA for Q1 2026 stood at -$3.6 million, down from $4.7 million in the prior quarter.
• The five-year high for EBITDA was $8.4 million in Q4 2024, with the low at -$7.1 million in Q1 2022.
• Historically, EBITDA has averaged -$1.6 million across 5 years, with a median of -$1.9 million in 2022.
• The largest YoY upside for EBITDA was 772.11% in 2024 against a maximum downside of 966.13% in 2024.
• Dna X's EBITDA stood at -$1.1 million in 2022, then dropped by 18.51% to -$1.3 million in 2023, then surged by 772.11% to $8.4 million in 2024, then sank by 44.74% to $4.7 million in 2025, then slumped by 177.62% to -$3.6 million in 2026.
• The last three EBITDA figures came in at -$3.6 million (Q1 2026), $4.7 million (Q4 2025), and -$4.0 million (Q3 2025), per Business Quant data.